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BIOTECH IN NORTHEAST OHIO CONFERENCE:
CURRENT PLANS AND VISIONS FOR THE
FUTURE
THE ROLE OF THE PRIVATE
SECTOR IN BIOTECHNOLOGY:
RESEARCH AND DEVELOPMENT
Lila Feiseet
THIS DISCUSSION WILL PRESENT the perspective of
the biotech industry. How can industry interface with entrepre-
neurs, investors, scientists, and researchers? One of the many
services that the Biotechnology Industry Organization (BIO)
provides is an annual meeting that will be held in San Diego,
California this year. Last year our annual meeting attracted over
12,000 people from a variety of different sectors: private, pub-
lic, investment, and from different countries. Our annual meet-
ing presents good partnering and education opportunities. Since
the completion of the first draft of the Human Genome in June
2000, there have been many questions raised in the ethical and
economic realms. These issues have provided a good place to
begin discussion. The biotechnology industry, as we all know,
is in its infant stages. It will take a lot of work on the part of all
of us here to be able to move forward and do things responsibly.
Let me just give you a little background. Since the early
1990s, there have been over 100 biotechnology drugs approved
for marketing in the United States and worldwide.' There are
350 more in the pipeline ready to be approved or rejected, and
270-million people worldwide have been helped because of
these biotech drugs.2 But that was not always the case. I am go-
ing to present a little history to begin the discussion.
t Director of Federal Government Relations and Intellectual Property, Bio-
technology Industry Organizations (BIO), Washington, D.C.
1 See BIOTECHNOLOGY INDUS. ORG., EDrroRs' AND REPORTERS' GUIDE TO
BIOTECHNOLOGY 9 (2001) (indicating over 117), available at http://www.bio.org/abo
utbio/guide2001/letter.pdf.
2 See id.
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Most of us know who Alexander Fleming was and that he
discovered penicillin. Some of us know that he did it in 1928,
but not many people can tell you who Andrew J. Moyer is and
why penicillin did not become commonly available until 1941,
almost a decade-and-a-half after it was discovered.
Andrew J. Moyer was a microbiologist with the U.S. De-
partment of Agriculture in Illinois. At the start of World War II,
the recognition that penicillin could treat wounded soldiers led
to international cooperation in looking for a way to mass-
produce the drug. In the U.S., Moyer was handed this assign-
ment and he set to work.
He found that by culturing the Penicillium mold in a culture
broth of corn steep liquor and lactose, penicillin yields rose
dramatically. He also discovered that in this medium, continu-
ous shaking further improved yields and the production rate.
Andrew J. Moyer holds patent numbers 2,442,141 and
2,443,989. We'll come back to this story.
One of the questions that is raised as a result of the comple-
tion of the Human Genome Project is, who should own biotech
inventions and why? This question is vital to the biotech indus-
try. The answers have spurred the growth of biotechnology, and
indeed, they will determine its future.
In answering this question we need to focus on a couple of
things that have allowed the industry to move forward. One is in
the area of the law, specifically patent law; and two, in the area
of what government in its infinite wisdom has done.
Okay, most of us know that the patent system took root in
the U.S. Constitution, but it really began over 600 years ago in
Europe when limited monopolies were granted. The basis in the
U.S. Constitution is Article I, Section 8, Clause 8. This is where
the government is given the mandate "[tlo promote the Progress
of Science and useful Arts, by securing for limited Times to Au-
thors and Inventors the exclusive Right to their respective Writ-
ings and Discoveries." 3 I underscore, Discoveries.
There have been a few other acts that have been passed
which address intellectual property protections; specifically, in
1790, 4 1930,' and the one in 1952,6 where the Patent Act allows
3 U.S. CONST. art I, § 8, cl. 8.
4 Patent Act of 1790, ch. 7, 1 Stat. 109 (1845). This was the first U.S. Patent
Act, which was amended in 1793 by a slightly longer act that is notable for its defini-
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an inventor to patent a composition of matter or improvement
on a composition of matter; also a process of making the com-
position of matter and a process of using it.
The law, however, forbids products of nature from being
patented, as well as laws of nature and mathematical algorithms.
Nothing in the Act precludes an extraction from nature to be
patented as long as it has been formed into a useful composition
of matter.
The courts have also upheld this. In 1979, in In re Bergy,7
the Court of Customs and Patent Appeals held that a biologi-
cally pure bacterial culture was patentable and not a product of
nature because this culture did not exist in nature in its purified
form and could only be produced under very controlled labora-
tory conditions.
In 1980, the Supreme Court also held, in Diamond v. Chak-
rabarty-some believe this was a landmark decision that al-
lowed for the progress of the biotech industry-that genetically
engineered bacteria useful for cleaning up oil spills were pat-
entable. In writing for the majority, Chief Justice Burger cited
the Congressional Committee Report accompanying the 1952
Act. He stated that, "Congress intended statutory subject matter
to 'include anything under the sun that is made by man."' 9 So,
the law is actually clear, very clear, on who should own biotech
innovations.
Interestingly, before 1980, which is when the Supreme
Court decision came out, there were only a handful of biotech
companies. The innovator at the time was Genentec; then, after
that, Cetus Chiron. But after Diamond v. Chakrabarty, the bio-
tech industry grew phenomenally. Some say it is a coincidence,
but I do not think so.
tion of what constitutes patentable subject matter in the United States. See Patent Act
of 1793, ch. 11, 1 Stat. 318 (1848).
5 Plant Patent Act of 1930, ch. 312, 46 Stat. 376 (1930).
6 Patent Act of 1952, ch. 950, 66 Stat. 797 (1952) (specifying, among other
criteria, that a composition of matter, or an improvement on the composition of mat-
ter, a process of making and a process of using the composition of matter make a
discovery patentable).
7 596 F.2d 952 (C.C.P.A. 1979), aff'd in part, 447 U.S. 303 (1980), and
rev'd in part, 444 U.S. 1028 (1980).
8 447 U.S. 303 (1980).
9 Id. at 309.
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There was another thing that helped in spurring the innova-
tion and the biotech industry. That was the work that the gov-
ernment did. The Bayh-Dole Act1° passed in 1980 by Congress
addressed transfer of technology from the public to the private
sector.
Since World War II, the U.S. Government had made sig-
nificant contributions to the world science and technology base.
Two of the major beneficiaries of federal spending at the time
were universities and U.S.-based corporations. Universities
benefited because the government would invest in something
that might not necessarily create a product, and business would
benefit because they could tap into what was created in univer-
sities and federal agencies in order to create a product.
Despite the perceived success, only five percent of the
28,000 patents that the government held at the time were trans-
ferred or licensed. That is an incredibly low amount. Most of
the research that was done prior to the 1970s sat on the shelf
gathering dust because no one had any incentive to do anything
with the research.
Bayh-Dole had two purposes. One was to allow universi-
ties, not-for-profit corporations, and small businesses to patent
and commercialize their federally funded inventions, and also to
allow these federal agencies to grant exclusive licenses for their
technology to provide more incentive to businesses.
Then we saw the growth of the biotechnology industry. To-
day there are over 1,300 biotech companies in this country
alone. These companies are developing effective new therapies
and cures for myriad diseases, including our most intractable
illnesses, such as heart disease, cancer, Alzheimer's, Parkin-
son's, and osteoporosis.
In fact, I read about a procedure that was done in San
Diego where transformed cells were injected directly into the
brain of an Alzheimer's patient. We do not know what will
come of it, but something will happen. This work was the col-
laborative effort between University of California at San Diego
and a small company in San Diego.
The U.S. biotech industry is the world's largest by far and
the most successful. It employs more than 150,000 people.1
1o Act of Dec. 12, 1980, Pub. L. No. 96-517, 94 Stat. 3015.
1 See BIOTECHNOLOGY INDUS. ORG., supra note 1, at 9-10 (indicating em-
ployment of 150,800).
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That is more than the toy and the sporting goods industries to-
gether. If you add in the jobs that are generated indirectly by the
biotech industry, the industry was responsible for nearly half a
million jobs last year and a total of nearly $50 billion in reve-
nue.
In Ohio there are over 350 biomedical companies-which
would include just a little broader group than just biotech com-
panies-that generate over $10 billion in revenue and employ
14,000 employees.
It is a sunny day for biotech now, but it is really easy for
things to change. The industry is very research intensive and
because our companies rely on private investment to support
their research, they and their investors on Wall Street are very
sensitive to public policy decisions. We saw evidence of this in
March of 1999, the day I call the "black day for biotechnology,"
when President Clinton, along with Prime Minister Blair, said
that genetic information should be publicly available. That day
the biotech industry lost $5 billion.
That is astronomical, but we recovered. Not as much as we
would like to, but we certainly did. And the good news is that a
little explaining about intellectual property, especially in the
case of gene patenting, can clear up a lot of questions.
Patents are not granted on broad DNA sequences of genes.
A patent is awarded only if an applicant or a person or an inven-
tor can describe a gene's role in human health or other commer-
cial applications. This is very clear in the patent office guide-
lines, published in the Federal Register.12
A patent does not have any impact on academic researchers
as long as they are not involved in commercial activity. Such
researchers are free to work without getting licensed from com-
panies or corporations. But without patents or intellectual prop-
erty protection there would be no biotech industry, there would
be no innovative drug development, or it would be dramatically
slowed down.
To develop a biotech drug, it takes hundreds of millions of
dollars, specifically $500 million, and somewhere between ten
and fourteen years time. For every five drugs that enter clinical
trials, only one is approved for patient use.
12 Utility Examination Guidelines, 66 Fed. Reg. 1092 (Dep't of Com-
merce Jan. 5, 2001).
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It is not hard to see here that intellectual property enabled
companies to sell their treatments and cures in order to raise the
revenues they need for further research and development. The
biotech industry in 1999 spent over $10 billion on research and
development, which is fifty percent of the $20 billion of reve-
nues that they generated in 1999.13
The case of penicillin is a perfect case of lost opportunity.
Fleming discovered it; he did not patent it; he did not know
what penicillin did. But because there was no patent, there was
no incentive for anyone to go forward and discover what it did.
Eventually a company secured a patent on the manufacturing
process and it was developed into a drug and then given to the
public.
There are lots of compounds in nature that the biopharma-
ceutical companies have developed into drugs and biologics; for
example, interferons, interleukins, and insulins. They are also
all found in nature, but they are not found in a form that is us-
able as a drug or biologic. If a company extracts one of these
from its natural setting and purifies it, identifies its structure,
and determines how it affects human health, then they can pat-
ent it.
The patent system does not apply purely to manmade or
synthetic inventions, because if we did not use what Mother Na-
ture has created, we would not be able to benefit from all that
there is in developing the perfect situation for health or for the
new century.
It is true that one cannot patent an element found in natural
form, but if you create a purified form of it that has industrial
use; for example, neon, then you can certainly secure a patent.
The United States leads the world in research and develop-
ment of biotech products. A key reason for this-and this could
be an answer to a lot of the questions that were raised-is the
government support of basic research at universities through
funding from the National Institutes of Health (NIH).
Breakthroughs in basic research can lead to life saving
therapeutics through cooperative efforts of the private and the
public sectors. In addition, businesses need the proper environ-
ment in order to be able to practice what they do best. If any of
you in this room can contact and work with the legislature, you
13 See BIOTECHNOLOGY INDUS. ORG., supra note 1, at 10 (indicating industry
statistics).
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can help to create a business environment that will allow bio-
tech industries to thrive. It is simply not enough to have a
mechanism here; you also need the environment to be able to
create and to grow.
We all know that the NIH is the preeminent American basic
medical research agency, but the NIH also knows the value of
intellectual property protection. For its contribution to the drug
development process in 2000, the NIH was paid $52 million in
royalty payments by the biopharmaceutical industry. Also in the
year 2000, the NIH obtained 120 U.S. patents, filed 189
applications, and executed 185 licenses and 109 cooperative
research and development agreements.
14
The NIH is doing its share in allowing the biotech industry
to move forward. In 1996, according to the Association of Uni-
versity Technology Managers Licensing Survey, of the $478
million in royalties that the universities received, eight-seven
percent of it, or $416 million, were from life science inventions,
most of which grew out of federal research grants.
As a result of the transfer of technology from the private
sector in the last year alone, twenty-three new biotech drugs
were approved for marketing in the year 2000.
Much of the basic research that yields these life saving
therapeutics could not happen without NIH-funded research.
But contrary to public opinion, NIH and government funded
research cannot create biotech therapies. They are not equipped
to do so. That is not their mission.
The notion that NIH research has spawned a biotech
revolution is a real one, though it is a bit oversimplified. In
most cases the government's role in bringing a new therapy to
market is far upstream from the high risk capital intensive de-
velopment and testing that biotech and pharmaceutical
companies undertake.
The biotech industry, which has more than doubled its
revenues in the past six years, spent a greater percentage of
those on research and development than any other industry.
Patent protection makes the investment of time and money
in biotech possible, and technology transfer allows for the trans-
14 OFFICE OF TECH. TRANSFER, NAT'L INST. OF HEALTH, NIH TECHNOLOGY
TRANSFER AcnvirEs-FY 1993 - FY 2001, available at http://ott.od.nih.gov/New
Pages/nih.html (last modified Jan. 10, 2002).
HEALTH MATRIX
fer of the information from universities and federal agencies to
the private sector.
Without the ability to exclusively license these particular
patents, biotech companies could not raise the hundreds of mil-
lions of dollars in capital that is required to create new medi-
cines.
There are some people in Washington that are calling for
what amounts to price controls on drugs that are developed from
federally funded basic research. Senator Wyden, Democrat of
Oregon, has said regarding the cancer drug Taxol: "This was
not a drug that came about through the genius of the private sec-
tor. It was a drug developed at the National Institutes of Health
by dedicated scientists who worked hard and were pushing with
every ounce of their strength to come up with new products to
help women." 15 He said this in response to the $1.5 billion that
Bristol-Myers Squibb had collected on Taxol.
But consider this-to develop Taxol, Bristol-Myers Squibb
invested approximately $1 billion. That does not include expen-
ditures for marketing, advertising or sales promotion, while the
NIH spent only $32 million. Not that $32 million is a small
number, but compared to $1 billion it is. Both of them spent an
estimated $65 million to $114 million in the Cooperative Re-
search and Development Agreement (CRADA).
To give you more evidence of how Bristol-Myers Squibb
conducted the majority of the research and spent the vast major-
ity of the money to develop Taxol, I offer the fact that the com-
pany's employees devoted more than 205 staff years to develop
Taxol in 1991 and 1992. This compares to 125 staff years that
was listed in the NIH CRADA.
These stats are not presented to discredit the efforts that
were put in by the NIH-sponsored scientists, but it is clear that
the U.S. system here provides the best vehicle for commerciali-
zation of basic research and eventually getting therapeutic drugs
to the patients who need them.
In the case of Taxol, the cooperative efforts of the public
and private sectors developed and brought to the market a life-
saving therapeutic. The lives that were saved due to this coop-
erative effort more than make up for the return on investment
for NIH.
15 146 CONG. REc. S5823-07 (statement of Sen. Wyden).
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The notion of price controls or what is called "reasonable
pricing" came up in the early 1990s and again it is beginning to
raise its head. Early in 1995 the NIH was told to review the
prices that companies set on federally funded research discover-
ies. The NIH director at the time, Harold Varmus, indicated that
the primary programmatic mission, legislative mandate, and ex-
pertise of NIH are in biomedical research, not in product pric-
ing. As a result of this, there was a fourfold increase in the NIH
CRADAS and creative cooperative research and development
agreements with biotech and pharmaceutical companies. This
just goes to show that without the looming threat of price con-
trol, a lot can be done in the area of biotech research.
In December of 1999, the NIH released the principles and
guidelines about NIH funding with respect to transferring re-
search materials and tools.16 These guidelines indicate that any
research tools that are developed as a result of federal funding
should be broadly accessible, and the definition of research
tools is very broad. It includes monoclonal antibodies, cell
lines, animal models, reagents, combinatorial chemistry librar-
ies, clones and cloning tools like PCRs, and even data bases and
computer software to the extent that they are used in unique re-
search tools.
In fact, last year a law was enacted that essentially gives
these guidelines the force of law.17 There are a lot of different
obstacles that are in the way of the biotech industry. I think a lot
can be done by creating a very nurturing environment, through
legislation and cooperative efforts with your state legislature to
enact tax incentives and research and development incentives to
allow for the growth of industry. Work closely with your public
officials to make sure that your State provides access to these
incentives. More importantly, keep the lines of communication
open with the biotech industry by participating in forums such
as this one to share ideas and concerns.
16 Principles and Guidelines for Recipients of NIH Research Grants and Con-
tracts on Obtaining and Disseminating Biomedical Research Resources, 64 Fed. Reg.
72,092 (final notice Dec. 23, 1999).
17 See Technology Transfer Commercialization Act of 2000, Pub. L. No.
106-404, 114 Stat. 1742.

